AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV prevention drug, lenacapavir.

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

PhRMA said in a January submission to the US trade review that US companies were the “constant target of compulsory licensing ...

Australian patent law includes mechanisms intended to address these concerns, but their effectiveness is questionable. Section 133 of the Patents Act permits compulsory licensing if reasonable ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

Pharma industry bodies have slammed a proposal by the European Commission to set up a compulsory licensing (CL) framework for medicines in emergency situations, claiming there is no need for the move.

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

AbbVie has struck an immuno-oncology licensing agreement with IGI Therapeutics that is potentially worth more than $1.9 billion to the clinical-stage biotechnology company.

Lupin Ltd has partnered with Zentiva Group to commercialize its biosimilar 'Certolizumab Pegol' across global markets. The ...

Pharma major Lupin has signed a USD 50 million agreement with a European pharmaceutical company. Lupin has entered into a ...

Pharma’s reliance on global supply chains and its need for vast quantities of water make it particularly vulnerable to climate change. But preparing to adapt to the phenomenon presents an ...

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug ...